Skip to content

Deciphering Disease Mechanisms Through Functional Genomics

Deciphering Disease Mechanisms Through Functional Genomics

Deciphering Disease Mechanisms Through Functional Genomics

Deciphering Disease Mechanisms Through Functional Genomics

Are you interested in learning about disease mechanisms through functional genomics? Join us for a webinar with Prof. Dr. Vijay Tiwari from the Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, UK & Institute of Molecular Medicine, SDU, Denmark. The webinar will take place in less than a week, on Wed, Apr 19, 2023, at 3:00 PM CET.

The research in Tiwari lab aims at achieving an integrated molecular and systems-level understanding of the communication between genetic and epigenetic information in determining cell identity and how this communication is altered in cancer and neurological disorders. To investigate these questions, Tiwari lab employs a multidisciplinary approach combining cutting-edge genomics and epigenetics together with computational biology tools in defined animal and cellular models. Most recently, using single-cell transcriptome profiles of TNBC patients, Tiwari lab has identified subclonal cell populations associated with chemoresistance. They further revealed the underlying gene regulatory circuitry and developed a first-in-class multi-gene assay for predicting chemotherapy response upfront for TNBC patients with high accuracy. Furthermore, they show that targeting these signature genes offers avenues to overcome resistance. These findings shed light on the mechanistic basis of chemoresistance while providing the best-in-class biomarker to predict chemotherapy response and alternate therapeutic routes for improved management of TNBC patients resistant to chemotherapy.

The format is the following:

  • 5 mins – introduction
  • 30 mins – main discussion
  • 10 min+ – Q&A

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Recent News

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Recent News

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

Recent News

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News

Inside Scailyte - Episode 8: Meet Sajid Maqbool

Meet Sajid Maqbool, our Information Technology Engineer at Scailyte AG. In our latest episode of "In...

Read more

Recent News

Inside Scailyte – Episode 7: Meet Anna Dimitrova

Meet Anna Dimitrova, our Chief Financial Officer at Scailyte AG. In our latest episode of "Inside Sc...

Read more

Recent News

01 /04

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

02 /04

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

03 /04

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News

04 /04

Inside Scailyte - Episode 8: Meet Sajid Maqbool

Meet Sajid Maqbool, our Information Technology Engineer at Scailyte AG. In our latest episode of "In...

Read more

Inside Scailyte – Episode 7: Meet Anna Dimitrova

Meet Anna Dimitrova, our Chief Financial Officer at Scailyte AG. In our latest episode of "Inside Sc...

Read more

Recent News